GlobeNewswire 1/28/2020 North American Travelan® sales up 98% in the first half of FY20
GlobeNewswire 1/8/2020 Immuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020
GlobeNewswire 11/21/2019 Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
GlobeNewswire 11/4/2019 Immuron Receives AUD $0.53M R&D Tax Concession Refund
GlobeNewswire 10/14/2019 Immuron North American Q1 Sales Up 111% YoY
GlobeNewswire 10/2/2019 New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluat...
GlobeNewswire 9/4/2019 U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains fro...
GlobeNewswire 8/16/2019 Immuron to Commence Non-Deal Investor Roadshow
GlobeNewswire 8/12/2019 BriaCell Appoints Richard J. Berman to Board of Directors
GlobeNewswire 8/8/2019 Immuron Reports Results in Severe Alcoholic Hepatitis Clinical Trial
GlobeNewswire 7/17/2019 Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments
GlobeNewswire 7/17/2019 Immuron Prices Underwritten Public Offering of ADSs
GlobeNewswire 7/16/2019 Immuron Announces Proposed Public Offering of ADSs
GlobeNewswire 7/16/2019 Immuron North American revenue surges by 52% in FY19
GlobeNewswire 6/25/2019 Immuron Directors Increase Shareholdings in the Company
GlobeNewswire 6/19/2019 Immuron to Commence US Non-Deal Institutional Investor Roadshow
GlobeNewswire 6/12/2019 US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
GlobeNewswire 5/30/2019 Immuron Announces the Closing of Public Offering of ADSs
GlobeNewswire 5/24/2019 Immuron Prices Underwritten Public Offering of ADSs
GlobeNewswire 5/23/2019 Immuron Announces Proposed Public Offering of ADSs
GlobeNewswire 4/30/2019 Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019
GlobeNewswire 4/17/2019 Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
GlobeNewswire 4/15/2019 Immuron sales surge by 66% in the Third Quarter of FY19
GlobeNewswire 4/11/2019 Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
GlobeNewswire 4/11/2019 Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea